MXCT · Company research
MaxCyte, Inc. Common Stock (MXCT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| An investor reports over 5% of MaxCyte (MXCT) after October 14 share purchases. - Stock Titan | An investor reports over 5% of MaxCyte (MXCT) after October 14 share purchases. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| 12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga | 12 Health Care Stocks Moving In Wednesday's Intraday Session Benzinga | View source ↗ | Benzinga | Oct 14, 2026 | neutral | 0 | 0.6 |
| Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? | Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? | Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. - Stock Titan | MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| MXCT stock holds steady as MaxCyte prepares next growth steps - AD HOC NEWS | MXCT stock holds steady as MaxCyte prepares next growth steps AD HOC NEWS | View source ↗ | AD HOC NEWS | Sep 4, 2026 | neutral | 0 | 0.6 |
| MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan | MaxCyte launches a gene-editing test that sees population-specific DNA variants Stock Titan | View source ↗ | Stock Titan | Aug 19, 2026 | neutral | 0 | 0.6 |
| MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness - Simply Wall Street | MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness Simply Wall Street | View source ↗ | Simply Wall Street | Aug 14, 2026 | neutral | 0 | 0.6 |
| $MXCT stock is up 19% today. Here's what we see in our data. - Quiver Quantitative | $MXCT stock is up 19% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 13, 2026 | neutral | 0 | 0.6 |
| $MXCT stock is up 19% today. Here's what we see in our data. - Quiver Quantitative | $MXCT stock is up 19% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 13, 2026 | neutral | 0 | 0.6 |
| $MXCT ($MXCT) Releases Q2 2026 Earnings - Quiver Quantitative | $MXCT ($MXCT) Releases Q2 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance | MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| MaxCyte (MXCT) Slips 5.56% as Shares Test Key Support Near $0.97 - Price Gap Fill - dars.gov.et | MaxCyte (MXCT) Slips 5.56% as Shares Test Key Support Near $0.97 - Price Gap Fill dars.gov.et | View source ↗ | dars.gov.et | Jul 27, 2026 | neutral | 0 | 0.6 |
| MXCT Forecast — Price Target — Prediction for 2027 - TradingView | MXCT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - AD HOC NEWS | MXCT stock holds steady as MaxCyte focuses on cell-therapy growth AD HOC NEWS | View source ↗ | AD HOC NEWS | May 9, 2026 | neutral | 0 | 0.6 |
| MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance | MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Mar 24, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 6, 2024 | neutral | 0 | 0.6 |
| What is the current Price Target and Forecast for MaxCyte (MXCT) - Zacks Investment Research | What is the current Price Target and Forecast for MaxCyte (MXCT) Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 9, 2022 | neutral | 0 | 0.6 |
| MaxCyte, Inc. (MXCT) Stock Price, News, Quote & History - Yahoo! Finance Canada | MaxCyte, Inc. (MXCT) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 30, 2021 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.